While anti-PD-1 treatment or pharmacological inhibition of SLC43A2 alone did not elicit significant anti-tumor effects, combination treatment synergistically increased CD8+ T cell function and infiltration, and decreased growth of mouse melanoma and ovarian tumors[203]. The gene discussed is CD8A; the disease is melanoma.